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LiposomesThe human glutamine/neutral amino acid transporter ASCT2 (hASCT2) was over-expressed in Pichia pastoris and
puriﬁed by Ni2+-chelating and gelﬁltration chromatography. The puriﬁed proteinwas reconstituted in liposomes
by detergent removal with a batch-wise procedure. Time dependent [3H]glutamine/glutamine antiport wasmea-
sured in proteoliposomes which was active only in the presence of external Na+. Internal Na+ slightly stimulated
the antiport. Optimal activity was found at pH 7.0. A substantial inhibition of the transport was observed by Cys,
Thr, Ser, Ala, Asn andMet (≥70%) and bymercurials andmethanethiosulfonates (≥80%). Heterologous antiport of
[3H]glutaminewith otherneutral amino acidswas also studied. The transporter showedasymmetric speciﬁcity for
amino acids: Ala, Cys, Val, Met were only inwardly transported, while Gln, Ser, Asn, and Thr were transported
bi-directionally. From kinetic analysis of [3H]glutamine/glutamine antiport Km values of 0.097 and 1.8 mM
weremeasured on the external and internal sides of proteoliposomes, respectively. The Km for Na+ on the exter-
nal sidewas 32 mM. The homology structuralmodel of the hASCT2 proteinwas built using the GltPh of Pyrococcus
horikoshii as template. Cys395 was the only Cys residue externally exposed, thus being the potential target of SH
reagents inhibition and, hence, potentially involved in the transport mechanism.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Amino acid transport systems play the pivotal role of maintaining
the amino acid homeostasis in mammalian cells. Among many trans-
porters involved in this function there is a group which shares speci-
ﬁcity for glutamine, thus playing the role of mediating glutamine
trafﬁcking in different tissues and intestinal and renal (re)absorption
[1–3]. A lot of functional data have been obtained by studying theacid; BCH, 2-aminobicyclo-
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B.V. Open access under CC BY-NC-ND transporters in cell systems such as cancer cell lines or Xenopus laevis
oocytes. Thus the glutamine-speciﬁc transporters have been ﬁrstly
classiﬁed on the functional basis. More recently the various trans-
porters have been assigned to different protein families (SLC) on the
basis of gene and primary structure analysis. Taking into account
both types of classiﬁcations, the glutamine-speciﬁc transporters can
be divided in sodium-dependent systems: system ASC/ATB0 (SLC1),
system B0,+ (SLC6), system y + L (SLC7), system N and A (SLC38)
and sodium-independent systems: system L (SLC7) and system b°,+
(SLC6). Some transporters can be further distinguished in tolerant
(N and y + L) or not tolerant (ASCT2) for the substitution of Na+
by Li+ or sensitivity towards inhibitors such as MeAIB (system A) or
BCH (System L, LAT1) [1–3]. However, several functional properties
of the amino acid transporters remain unknown or controversial,
due to some limitations of the cell experimental models given by
the contemporary presence of similar transport systems and/or
enzymes which could affect the transport assays and by the difﬁcult
access to the internal side. Most of these problems can be overcome
using simpler models for studying transport, such as the proteoliposome
experimental systemwhich revealed suitable for studying functional and
kinetic properties of transporters [4,5]. Concerning the structure ofmam-
malian amino acid transporters no crystallographic data is available so
far. High resolution structures have only been achieved for somelicense.
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these structures, homology models have been obtained for mammalian
amino acid transporters, some of which have been in part validated by
chemical targeting [8–10]. Very interestingly the expression of some of
the transporters responsible for glutamine trafﬁcking is up-regulated in
tumors [2]. Cancer cells, in fact, require high amounts of glutamine for
energy and growth purposes [2,11]. In this scenario it becomes clear
that the study of glutamine transporters is a hot research topic and strat-
egies for over-expressing the transporters in large scale and studying
their structure/function relationships are very welcome. Among the
most interesting transporters in human physiology and pathology
there is the Na+-dependent glutamine/neutral amino acid transporter
ASCT2 (SLC1A5) previously known in humans as ATB0. This transport
systemhas been identiﬁed in human cell systems even though the kinet-
ic properties and substrate speciﬁcity are not fully understood [2,3,12]
while the rodent isoform, besides being studied in cell systems
[13–16], has been also functionally and kinetically characterized in
proteoliposomes [9,17,18]. Basic functional and kinetic parameters of
the kidney rat protein determined in both experimental models corre-
lated well. Novel functional properties such as the ATP regulation, the
internal side Km, the reaction mechanism, and the pH dependence of
glutamate transport were revealed using proteoliposomes [17,18].
Due to its over-expression in cancer cells, ASCT2 has been proposed as
a potential target for antitumor drugs [2]. Very recently, a molecular
screening of ditiazoles, potent inhibitors of the rat ASCT2, has been
carried out in proteoliposomes [19]. These results highlighted the im-
portance of obtaining the recombinant human ASCT2 for performing
structural, functional and inhibition studies. In this work, the high
level production of the human ASCT2 in Pichia pastoris is described.
The function of the transporter extracted from yeast membranes has
been assayed in proteoliposomes where the protein has been inserted
in a right-side-out orientation (see Discussion) with respect to the cell
membrane, thus constituting a suitable tool for unequivocal functional
characterization and interaction studies with potential drugs.
2. Materials and methods
2.1. Materials
The P. pastoriswild type strain (X-33), the pPICZB vector, NuPAGE®
4–12% Bis-Tris Gels were purchased from Invitrogen; restriction endo-
nucleases and other cloning reagents from Fermentas; PD-10 columns,
Superdex 200 10/300 GL, ÄKTA FPLC system, ECL plus, Hybond
ECL membranes and L-[3H]glutamine from GE Healthcare; Ni-NTA
agarose and polypropylene columns from Qiagen, anti His6 antibody
from Clontech; the anti mouse IgG HRP conjugate from Promega;
C12E8 from Anatrace; Amberlite XAD-4, egg yolk phospholipids
(3-sn-phosphatidylcoline from egg yolk), Sephadex G-75, L- glutamine
and all the other reagents were from Sigma-Aldrich.
2.2. Cloning of hASCT2
The wild type gene was isolated from total RNA of primary human
ﬁbroblasts by reverse transcription. Initially, the 1623 bp cDNA
encoding hASCT2 (GenBank NM_005628.2, SLC1A5) was ampliﬁed
using the forward primer NdeI-hASCT2: 5′-G GAA TTC CAT ATG GTG
GCC GAT CCT CCT CG-3′ and the reverse primer HindIII-hASCT2:
5′-CCC AAG CTT TTA CAT GAC TGA TTC CTT CTC-3′, respectively. The
ampliﬁed cDNA sequence was veriﬁed by sequencing using the ABI
310 automated sequencer Applied Biosystems. For subsequent cloning
to P. pastoris, the full length cDNA coding for hASCT2 was ampliﬁed
using the forward primer EcoRI-hASCT2: 5′-ATA CCG GAA TTC AAA
ATG GTT GCC GAT CCT CCT CGA GAC TCC-3′ and the reverse primer
XbaI-hASCT2: 5′-A TAC TAG TCT AGA TCA ATG ATG ATG ATG ATG ATG
CAT GAC TGA TTC CTT CTC AGA GGC-3′, coding a C-terminal His6 tag.Restriction sites are underlined and the Kozak consensus sequence is
shown in bold.
The hASCT2 gene was codon optimized for P. pastoris by GenScript
and the artiﬁcial cDNA included a 5′ EcoRI restriction site plus the Kozak
consensus sequence and a 3′ XbaI restriction site plus a C-terminal His6
fusion tag. In the optimized gene, the Codon Adaptation Index (CAI)
[20] was upgraded from 0.51 (wild type) to 0.82 (optimized) and the
GC contentwas decreased from63.01% to 45.43%. For cloning in P. pastoris
both the wild type gene (wt-hASCT2) and the optimized gene
(Opt-hASCT2) were inserted in the EcoRI/XbaI sites of the pPICZB expres-
sion vector, resulting in two different recombinant constructs, deﬁned as
pPICZB-(wt)hASCT2-His6 and pPICZB-(Opt)hASCT2-His6. Both constructs
were veriﬁed by sequencing.
2.3. Recombinant production of hASCT2
To obtain the recombinant hASCT2-His6 protein, the resulting plas-
mids were linearized with PmeI and the transformation into the P.
pastoris wild type strain X-33 was performed by electroporation [21].
To select putative multi-copy recombinants a total of 52 transformants
for each construct were tested for growth on YPDS plates containing
2000 μg/mL Zeocin and analyzed after 3 days. Small-scale production
was performed in triplicates in shake ﬂask cultures as previously
described [22]. For large scale protein production, P. pastoris strains
producing recombinant hASCT2 (X33/pPICZB-(wt)hASCT2-His6 and
X33/pPICZB-(Opt)hASCT2-His6)were grown at 30 °C in a 3 L fermentor
(Infors HT) having an Initial Fermentation Volume (IFV) of 1.5 L basal
salt medium [23] containing 6.53 mL PTM1 trace salts [24]. An over-
night pre-culture of 75 mL in BMGY having an OD600 of about 4 was
used to inoculate the fermentor. The initial glycerol volume was
consumed after approximately 24 h and the culture was fed with
150 mL 50% glycerol (v/v) for 24 h to increase biomass. To induce
production of recombinant hASCT2, the culture was fed with 150 mL
methanol for 48 h. To obtain the membrane fraction, P. pastoris cells
overproducing hASCT2 were resuspended in buffer A (50 mM Tris,
pH 7.4, 150 mM NaCl, 6 mM β-mercaptoethanol and 0.5 mM PMSF)
at a concentration of about 1 g/mL. Droplets of the cell suspension
were frozen in liquid nitrogen and cells were broken by an X-Press
(four passages). The suspension was centrifuged at 6000 g for 30 min
and the supernatant containing membrane and cytosolic fractions
(crude extract) was collected. This supernatant was ultracentrifuged
in a Ti45 rotor at 140,000 g for 1 h. The resulting membrane pellet
was washed with urea buffer (5 mM Tris pH 7.4, 2 mM EDTA, 2 mM
EGTA and 4 M urea) and then again ultracentrifuged as above. The
washed membrane fractions (pellet) containing (wt)hASCT2 or (Opt)
hASCT2 were resuspended in buffer B (25 mM Tris, pH 7.4, 250 mM
NaCl, 6 mM β-mercaptoethanol and 10% glycerol) at a ﬁnal concentra-
tion of about 300 mg/mL and homogenized using a handheld electric
homogenizer. Aliquots of 6 mL of the membrane fraction were stored
at −80 °C. Various stages from the protein puriﬁcation procedure
were analyzed by SDS-PAGE and immunoblot.
2.4. Solubilization and puriﬁcation of hASCT2
For large-scale solubilization and puriﬁcation (Opt)-hASCT2, about
1.5 g of washed membranes (300 mg/mL) was resuspended in buffer
B containing 1% C12E8 (w/w) to a concentration of 150 mg/mL and
gently mixed by agitation for 3 h at 4 °C. After solubilization, the sol-
ubilized material was centrifuged at 120,000 g for 1 h, imidazole
(50 mM) was added to the supernatant which was mixed with
3 mL Ni-nitrilotriacetic acid (NTA) agarose resin equilibrated with
the equilibration buffer (20 mM Tris pH 7.4, 300 mMNaCl, 10% glyc-
erol, 6 mM β-mercaptoethanol, 0.03% C12E8, and 50 mM imidazole)
and incubated by gentle agitation for 3 h at 4 °C. The Ni-NTA resin
was subsequently packed into a plastic 1 mL column. The resin was
washed with 30 mL of the equilibration buffer. Then, 4 mL of the
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containing 500 mM imidazole (referred as elution buffers)were added.
Fractions of 1 mL were collected; fractions 2–4 were pooled and
desalted on a PD-10 desalting column pre-equilibrated with desalting
buffer (20 mM Tris pH 7.4, 100 mM NaCl, 10% glycerol, 6 mM
β-mercaptoethanol and 0.03% C12E8), fromwhich 3.5 mLwas collected.
Desalted protein was concentrated to 250 μL by vacuum Vivaspin 30 K
spin concentrator and loaded onto a Superdex 200 10/300 GL column
pre-equilibrated with desalting buffer, and eluted with the same buffer
using the ÄKTA FPLC system. Fractions of 500 μL were collected and an-
alyzed by SDS-PAGE. The total protein concentration of each fraction
was determined by Bradford protein assay using bovine serum albumin
(BSA) as a standard (Bio-Rad DC Protein assay). Protein samples were
analyzed by precasted SDS-PAGE on NuPAGE® 4–12% Bis-Tris Gels
under reducing conditions with 20 mM DTT. The gel was stained with
SimplyBlue™ SafeStain (Invitrogen). Immonoblotting analysis was
performed using anti-His6 antibody 1:5000. To verify the identity of
the recombinant protein the puriﬁed fraction was analyzed by
SDS-PAGE, the band of interest excises and analyzed bymass spectrom-
etry as previously described [25].
2.5. Reconstitution of the hASCT2 into liposomes
The puriﬁed hASCT2 was reconstituted by removing the deter-
gent using the batch-wise method. In this procedure, the mixed
micelles containing detergent, protein and phospholipids were in-
cubated with 0.5 g Amberlite XAD-4 resin under rotatory stirring
(1400 rev/min) at room temperature (25 °C) for 40 min [26]. The
composition of the initialmixture used for reconstitutionwas: 100 μL of
the solubilized protein (5 μg protein), 120 μL of 10% C12E8, 100 μL of
10% egg yolk phospholipids (w/v) in the form of sonicated liposomes
prepared as previously described [5], 10 mM L-glutamine, and 20 mM
Tris/HCl pH 7.0 (except where differently speciﬁed) in a ﬁnal volume
of 700 μL. All the operations were performed at 4 °C.
2.6. Transport measurements
To remove the external substrate for uptake experiments, 600 μL of
proteoliposomes was passed through a Sephadex G-75 column (0.7 cm
diameter × 15 cm height) preequilibrated with 20 mM Tris/HCl pH 7.0
and sucrose at an appropriate concentration to balance the internal osmo-
larity. Transport (uptake) measurement was started by adding 50 μM
[3H]glutamine and 50 mMNa-gluconate (except where differently spec-
iﬁed) to the proteoliposomes. For efﬂux measurements, proteoliposomes
(600 μL), containing 10 mM glutamine, were preloadedwith radioactivi-
ty by transporter-mediated exchange equilibration [27] by incubation
with 50 μM [3H]glutamine at high speciﬁc radioactivity (2 μCi/nmol)
and 50 mM Na-gluconate for 120 min at 25 °C. External compounds
were removed by another passage of the proteoliposomes through
Sephadex G-75 as described above. Transport (efﬂux) measurement
was started by adding non radioactive substrates to the preloaded
proteoliposomes. In both uptake and efﬂux assays, transportwas stopped
by adding 10 μMmersalyl at the desired time interval. In control samples,
the inhibitorwas added at time zero according to the inhibitor stopmeth-
od [28]. The assay temperature was 25 °C. At the end of the transport
assay, each sample of proteoliposomes (100 μL) was passed through a
Sephadex G-75 column (0.6 cm diameter × 8 cm height) to separate
the external from the internal radioactivity. Liposomes were eluted with
1 mL 50 mMNaCl and collected in 4 mL of scintillationmixture, vortexed
and counted. For the determination of [3H]glutamine uptake, the experi-
mental values were corrected by subtracting the respective controls
(samples inhibited at time zero); the initial rate of transport was mea-
sured by stopping the reaction after 10 min, i.e., within the initial linear
range of [3H]glutamine uptake into the proteoliposomes. For the determi-
nation of [3H]glutamine efﬂux the experimental values at each timewere
subtracted from the radioactivity initially present in the proteoliposomesat time zero. Fitting of experimental data in a ﬁrst order rate equation to
obtain rate constantswas performedusing the non linear regression anal-
ysis Graﬁt software (version 5.0.13).
To measure the speciﬁc activity of hASCT2, the amount of
reconstituted recombinant protein was estimated from Coomassie
blue stained SDS-PAGE gels by using the Chemidoc imaging system
equipped with Quantity One software (Bio-Rad) as previously
described [29].
2.7. Homology modeling of hASCT2
The homology structural model of the hASCT2 was built using the
glutamate transporter homologue from Pyrococcus horikoshii crystal
structure (1XFH) as template. The amino acid sequence of the rat
ASCT2 (NP_786934) and the glutamate transporter (NP_143181) was
aligned manually using ClustalW as described in Ref. [6] and adjusted
for hASCT2, belonging to the same family of glutamate and neutral
amino acid transporters as rASCT2. The optimized alignment was used
to run the program Modeller 9.11 [30].
3. Results
3.1. Over-production and puriﬁcation of hASCT2
To identify high producing P. pastoris clones, a high zeocin screen
was performed followed by a small scale production test in 25 mL
cultures to verify proper membrane localization of recombinant
hASCT2 (data not shown). From these tests, the positive clones for
the following large scale production were obtained. To achieve higher
production levels of (wt)hASCT2 and (Opt)hASCT2 (obtained by the
cDNA optimized for P. pastoris, coding the same hASCT2 protein as
the wt cDNA), the growth was scaled up in a 3 L fermentor to supply
the high oxygen demand of P. pastoris. Cultivating X-33/(wt)hASCT2
and X-33/(Opt)hASCT2 under tightly controlled regimes resulted in
a total cell mass of 350 g wet weight.
Under this culture condition high yields of an over-produced protein
with an apparent molecular mass of about 50 kDa were observed both
in the X-33/(wt)hASCT2 and X-33/(Opt)hASCT2 (Fig. 1A). The protein
was identiﬁed as the hASCT2 in crude extract and membrane fractions
by immunoblotting using an anti-His antibody (Fig. 1B). The yield of
(Opt)hASCT2 was more than two-fold as compared to the (wt)
hASCT2. Thus, in all the experiments hASCT2 from X-33/(Opt)hASCT2
was used. One or two higher molecular mass bands were detected by
the immunostaining, corresponding to double and triple apparent mo-
lecular mass of the hASCT2 monomer (Fig. 1B).
Before puriﬁcation, a solubilization trial was carried out on the
membrane fraction to ﬁnd a suitable detergent. Nine different de-
tergents (Cholate, DDM, Brij35, LDAO, β-octylglucoside, CHAPS,
Fos-choline-12, Triton X-100, C12E8) were tested. DDM, LDAO,
Fos-choline-12 and C12E8 showed the best efﬁciency in solubilizing
hASCT2 (not shown), although only C12E8 revealed to be suitable for
protein reconstitution in liposomes (see below). For large scale puriﬁca-
tion, urea washed membranes extracted from the X33/(Opt)hASCT2
were solubilized with 1% C12E8. The solubilized protein (Fig. 2A lane
1)was incubatedwith the Ni-NTA agarose resin. After washing, virtual-
ly all the unbound proteins were removed and most of the protein was
found in fractions 2–4 after elution (1 ml each) in 300 mM imidazole
(Fig. 2A lanes 3–5). The addition of the same elution buffer containing
500 mM imidazole led to a further recovery of small amounts of
hASCT2 as observed in fractions 5–6 (Fig. 2A, lanes 6–7). The puriﬁed
fractions contained a 50 kDa protein besides the two higher molecular
mass bands corresponding to dimeric and trimeric forms of the protein
whichwere veriﬁed by the immunoblot (Fig. 2B). To conﬁrm the corre-
spondence of the puriﬁed bands with the hASCT2 protein, mass spec-
trometry analysis was also performed. Only peptides containing the
hASCT2 sequence (Table 1) were recognized after trypsin treatment of
Table 1
Mass values and amino acid sequence obtained by mass spectrometry analysis of the
tryptic peptides of recombinant hASCT2.
Peptide mass (Da) Sequence position Peptide sequence
984.51 2–10 VADPPRDSKa–c
1277.67 179–189 EVLDSFLDLARa
1135.49 203–211 SYSTTYEERa–c
1096.64 248–257 LGPEGELLIRa,b
1062.49 363–372 CVEENNGVAKa
1143.62 493–502 STEPELIQVKa–c
1102.54 526–537 GPAGDATVASEKa–c
1133.52 363–372 cVEENNGVAKa–c
801.39 1–7 mVADPPRa–c
1131.55 1–10 mVADPPRDSKa–c
m: oxidation.
c: propionamide.
a Peptides from monomer.
b Peptides from dimer.
c Peptides from trimer.
Fig. 1. Production of (wt)hASCT2 and (Opt)hASCT2 using fermentor growth. (A) SDS-PAGE
(4–12%) gel electrophoresis analysis of the hASCT2 production stained as described inMa-
terials andmethods. M: proteinmarkers; lanes 1–2, crude extract from P. pastoris cells pro-
ducing (wt)hASCT2 (lane 1) or (Opt)hASCT2 (lane 2) in the fermentor; lanes 3–4:
membrane fraction from P. pastoris cells producing (wt)hASCT2 (lane 3) or (Opt)hASCT2
(lane 4) in the fermentor. In each lane 10 μg total protein was loaded. (B) Immunoblot
using an anti-His antibody showing hASCT2 production of the same protein fractions as
in (A). In lanes 1 and 2, 50 μg total protein was loaded, in lanes 3 and 4, 1 μg total protein
was loaded.
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puriﬁed fraction (Fig. 2). These higher molecular mass bands of
hASCT2 are probably formed by monomers tightly interacting or cova-
lently cross-linked and could not be dissolved by SDS. Protein fractionsFig. 2. Puriﬁcation of (Opt)hASCT2. (A) SDS-PAGE (4–12%) gel electrophoresis analysis of
the (Opt)hASCT2 puriﬁcation stained as described in Materials and methods. M: protein
markers; lane 1: membrane fraction from P. pastoris cells producing (Opt)hASCT2 in the
fermentor (10 μg) solubilizedwith 1%C12E8; lanes 2–5: fractions 1–4 fromNi-NTA afﬁnity
chromatography eluted with 300 mM imidazole elution buffer; lanes 6–7: fractions 5–6
from Ni-NTA afﬁnity chromatography eluted with 500 mM imidazole elution buffer;
lane 8: pooled puriﬁed fractions 2–4 after desalting on PD10 column. (B) Immunoblot
of puriﬁed protein on lane 8 using an anti-His antibody.with apparent monomeric molecular mass on SDS-PAGE could be iso-
lated from the higher molecular mass products by size exclusion chro-
matography using a Superdex 200 column (Fig. 3). However, most of
the oligomeric forms of hASCT2 were eluted in the fractions corre-
sponding to the void volume (lanes 1–3) of the column or to very
high molecular masses (lanes 4–7), indicating that these protein
forms were mostly super-aggregated. While, most of the protein with
apparent molecular mass of 50 kDa on SDS-PAGE (Fig. 3 lanes 8–11)
eluted in the fractions corresponding to about150 kDa, indicating that
the non-aggregated protein was most likely in a trimeric form before
SDS treatment. The ﬁnal protein yield after the puriﬁcation procedure
was estimated to be 10 mg per liter of cell culture.
3.2. Optimization of the reconstitution
The reconstitution procedure previously established for the
rASCT2 [17] was not effective as it is, for reconstituting the hASCT2.
The procedure of detergent removal had to be changed from cyclic
column passages to batch-wise procedure to prolong the time of incu-
bation of the reconstitution mixture with the hydrophobic resin.
Moreover, some parameters which are known to be critical for the
detergent removal reconstitution method had to be modiﬁed. The
detergent/lipid ratio was increased from 0.95 (w/w), used for the
rat protein, to 1.2 (w/w); while the amount of protein in the reconsti-
tution mixture was reduced from 30 to 5 μg.
3.3. Functional characterization
The time dependence of the transport activity was measured as
50 μM [3H]glutamine uptake in proteoliposomes, under different
conditions (Fig. 4A). The uptake of [3H]glutamine in the presence of
external Na+ into the proteoliposomes containing internal glutamine,
increased as function of the time up to 90 min i.e., when the radioac-
tivity equilibrium was reached; if Na+ was present also inside the
proteoliposomes a stimulation of the uptake was observed. On the
contrary, no [3H]glutamine uptake was detected in the absence of
external Na+ even in the presence of internal Na+. Moreover, nearly
no [3H]glutamine uptake could be detected into vesicles without in-
ternal substrate or with lower internal glutamine concentration
(50 μM) even in the presence of internal Na+ (Fig. 4A). No transport
was observed in proteoliposomes reconstituted with boiled protein,
demonstrating that glutamine antiport was mediated by the hASCT2
protein. The experimental data ﬁtted a ﬁrst order rate equation
from which a rate constant, k, of 0.039 min−1 and a transport
rate (the product of k and the transport at equilibrium) of
4.67 nmol·min−1·mg protein−1 were calculated in the absence of
internal Na+; in its presence a rate constant, k, of 0.0279 min−1
Fig. 3. SDS-PAGE analysis of (Opt)hASCT2 size exclusion chromatography. A total of
250 μL of desalted puriﬁed hASCT2 was loaded onto a Superdex 200 size exclusion col-
umn and eluted with 20 mM Tris pH 7.4, 100 mM NaCl, 10% glycerol, 6 mM
β-mercaptoethanol and 0.03% C12E8. Fractions of 0.5 mL were collected and analyzed
by SDS-PAGE (4–12%). M: protein markers; lanes 1–12 protein fractions from 8 mL
to 14 mL volume column. Fractions 8–11 correspond to a molecular mass of about
150 kDa according to standard calibration of the column manufacturer.
Fig. 4. [3H]glutamine uptake by hASCT2 reconstituted in proteoliposomes: effects of
external and internal Na+. (A) The reconstitution was performed as described in Ma-
terials and methods. Transport was started by adding 50 μM [3H]glutamine at time
zero to proteoliposomes reconstituted with hASCT2 (●,□, Δ) or with protein treated
for 20 min at 100 °C (○), in the absence (□, ⋄) or presence (●,○, Δ, ▲, ⋄) of 50 mM
external Na-gluconate; 10 mM glutamine (●, ○, □, ▲, ⋄), 50 μM glutamine (⋄) or
no internal substrate (Δ) was present inside the proteoliposomes. In (⋄,⋄) 20 mM in-
ternal Na-gluconate was present. The transport reaction was stopped at the indicated
times, as described in Materials and methods. Results are means ± S.D. from three ex-
periments. (B) The reconstitution was performed as described in the Materials and
methods except that Na+-gluconate (dark bars), and K-gluconate (gray bars) were
added into proteoliposomes at the concentrations: 5, 10, 20 and 50 mM; light gray
bars indicates intraliposomal sucrose at concentrations: 10, 20, 40, 100 mM; white
bar, no additions. Transport was started by adding 50 μM [3H]glutamine at time zero
to proteoliposomes together with extraliposomal 50 mM Na+-Gluconate. The trans-
port reaction was stopped at 90 min, as described in Materials and methods. Results
are means ± S.D. from three experiments. *Signiﬁcantly different from sample with-
out added inhibitor as estimated by Student's t test (P b 0.05).
Fig. 5. Effect of pH on hASCT2 transport activity. The reconstitution was performed as
described in Materials and methods except that 20 mM Tris/HCl at the indicated pH
was used. Transport was started by adding 50 μM [3H]glutamine in 20 mM Tris/HCl
at the indicated pH to proteoliposomes containing 10 mM glutamine, in the presence
of 50 mM external Na-gluconate. Results are means ± S.D. from three experiments.
2242 P. Pingitore et al. / Biochimica et Biophysica Acta 1828 (2013) 2238–2246and a transport rate of 5.0 nmol·min−1·mg protein−1 were calculated.
Fig. 4B shows the effects of different concentrations of intraliposomal
Na+. The stimulation of transport was maximal at 20 mM (40 mOsM)
internal Na+ and did not increase at higher concentration. No stimula-
tionwas observed if Na+was substituted by K+ or by sucrose, indicating
that the observed effect was speciﬁcally exerted by Na+. The depen-
dence of the glutamine antiport on the pH has been studied (Fig. 5).
Maximal transport activity was observed at pH 7.0. At more acidic or al-
kaline pH the activity drastically decreased.
3.4. Amino acid and inhibitor speciﬁcity
The effect of externally added amino acids on the glutamine antiport
was analyzed (Fig. 6). Cysteine, threonine, serine, alanine, and aspara-
gine, were the most efﬁcient in inhibiting the transport with more
than 80% inhibition at amino acid concentration of 1 mM. Inhibition
between 70 and 40% was exerted by methionine, valine and leucine.
The extent of inhibition decreased to less than 40% for tyrosine and
less than 20%, or insigniﬁcant, for the other amino acids. The amino
acid analog MeAIB and BCH did not inhibit at all the transporter
(Fig. 6). The sensitivity to chemical compounds known to interact
with speciﬁc amino acid residues of proteins was also investigated
(Fig. 7). The SH reagents HgCl2, mersalyl and pOHMB were the
most potent inhibitors, followed by methanethiosulfonates, while
maleimides (NEM, PEM) and the NH2 reagent PLP had lower inhibitory
effects. The histidine reagent DEPC did not exert any inhibitory effect on
[3H]glutamine uptake. To establish which of the amino acids could be
transported by the antiport reaction catalysed by the reconstituted
hASCT2, the experiments of Fig. 8 have been performed. [3H]glutamine
uptake was measured in proteoliposomes containing different amino
acids as counter substrates. Serine, asparagine and threonine efﬁciently
stimulated [3H]glutamine uptake, i.e., were transported by ASCT2 as
efﬂux substrates from the intraliposomal compartment. Surprisingly,
alanine and cysteine, even though revealed to be good inhibitors of
[3H]glutamine uptake, could not be transported (Fig. 8A), as well as
valine, methionine, histidine, glutamate and arginine, tested among
the non-inhibiting amino acids; the same results were obtained when
20 mM internal Na+was present (not shown). Alternatively, [3H]gluta-
mine efﬂux from prelabeled proteoliposomes was measured in thepresence of externally added amino acids (Fig. 8B). Serine, asparagine,
threonine, alanine and cysteine revealed to strongly stimulate efﬂux
of [3H]glutamine, i.e. could be inwardly transported in antiport with
glutamine. Valine and methionine were also inwardly transported
Fig. 6. Effect amino acids and substrate analogs on hASCT2 transport activity. The re-
constitution was performed as described in Materials and methods. Transport was
started by adding 50 μM [3H]glutamine to proteoliposomes containing 10 mM internal
glutamine, in the presence of 50 mM external Na-gluconate. The molecules were
added 1 min before the labeled substrate at the concentration 1 mM. Percentage of in-
hibition was calculated for each experiment with respect to the sample without added
inhibitor. Results are means ± S.D. from three experiments. *Signiﬁcantly different
from sample without added inhibitor as estimated by Student's t test (P b 0.05).
Fig. 7. Effect of protein speciﬁc reagents on hASCT2. The reconstitution was performed as
described in Materials and methods. Transport was started by adding 50 μM [3H]gluta-
mine to proteoliposomes containing 10 mM internal glutamine, in the presence of
50 mM external Na-gluconate. The molecules were added 1 min before the labeled sub-
strate at the following concentrations: 0.02 mM HgCl2, mersalyl, p-OHMB; 1 mM
MTSEA, MTSET, NEM or PEM; 10 mM PLP; 4 mM DEPC. Percentage of inhibition was cal-
culated with respect to the sample without added inhibitor. Results are means ± S.D.
from three experiments. *Signiﬁcantly different from sample without added inhibitor as
estimated by Student's t test (P b 0.05).
Fig. 8. Amino acids as counter substrates for hASCT2. The reconstitutionwas performed as
described in Materials and methods. (A) The indicated substrates (10 mM) were present
in the intraliposomal space (included in the reconstitution mixture). Transport was
started by adding 50 μM [3H]glutamine to the proteoliposomes in the presence of
50 mM external Na-gluconate. Percentage glutamine uptake was calculated for each ex-
periment with respect to proteoliposomes containing 10 mM internal glutamine
(100%). (B) Proteoliposomes were preloaded with 50 μM [3H]glutamine and its efﬂux
was measured in the presence of 10 mM of the indicated external amino acid. The efﬂux
experiment was performed as described in Materials and methods and percentage gluta-
mine efﬂuxwas calculated for each experiment with respect to proteoliposomeswith ex-
ternally added glutamine (100%). Results are means ± S.D. of the percentage of three
experiments. *Signiﬁcantly different from samples without internal or external substrate
as estimated by Student's t test (P b 0.05).
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were not transported.
3.5. Kinetics of ASCT2 mediated transport
The dependence of the transport rate on the glutamine
concentration was studied. The initial rate of glutamine antiport
(Fig. 9A) showed a dependence on the external glutamine
concentration ﬁtting the Michaelis–Menten equation, from which
half-saturation constant (Km) of 0.097 ± 0.019 mM and a Vmax
of 13.3 ± 1.9 nmol·min−1·mg protein−1 (from three different ex-
periments) were derived. A similar experiment was performed to
obtain information on the intraliposomal Km, which resulted to
be much higher than the external one (Fig. 9B). The measured
value was 1.8 mM ± 0.52 (from three different experiments).
The calculated Vmax (12.0 ± 1.5 nmol·min−1·mg protein−1)
was similar to that measured in the experiment of Fig. 9A.
The dependence of the transport on the concentration of external
cations, as gluconate salts, was studied. The data of Fig. 9C shows that
the transport rate of glutamine antiport, starting from zerowas strongly
stimulated by external Na+. The data could be ﬁtted in the Michaelis–
Menten equation from which a Vmax of 11.5 ± 0.57 nmol·min−1·mg
protein−1 and a Km of 32 ± 4.7 mM were calculated. The presence of
Li+ or K+ in the extraliposomal compartment was not able to stimulate
the glutamine transport.
4. Discussion
One of the major challenges concerning the study of mammalian and
especially human transporters is to obtain sufﬁcient amount of puriﬁed
proteins for both structural and functional characterization. Moreover,
the availability of suitablemethods for transport assay is essential to char-
acterize recombinant proteins obtained by heterologous production. Only
in recent years, the number of successful over-production trials of mam-
malian and human transporters is slightly increasing. Over-production
has been achieved using Escherichia coli as host, both as entire organism
[31,32] or in cell free systems [33]. However, in several cases it was not
possible to obtain signiﬁcant levels of human proteins in bacteria, thus
suggesting another host for production. This was the case for hASCT2
which was toxic to several bacterial strains screened for expression trials
(data not shown). Using the yeast P. pastoris we succeeded in obtaining
high levels of recombinant hASCT2, similar to the recently expressed
hLAT2 transporter [34]. hLAT2 and hASCT2 represent the only mammali-
an amino acid transporters produced in yeast, so far. hASCT2 is structural-
ly unrelated to hLAT2, but presents signiﬁcant homology to glutamatetransporters [6,9]. An important step for increasing the yield of recombi-
nant hASCT2 protein was the optimization of the codons to the yeast
translation machinery. Similarly, bacterial over-production of a different
transporter, OCTN2, was obtained only after codon bias [35]. Noteworthy,
the over-produced hASCT2 was associated to the yeast membrane
Fig. 9. Dependence of substrate concentration and the rate of glutamine antiport. The
transport rate was measured adding [3H]glutamine at the indicated concentration to
proteoliposomes containing 10 mM internal glutamine (A) or 200 μM [3H]glutamine
to proteoliposomes containing internal glutamine at the indicated concentrations
(B), in the presence of 50 mM external Na-gluconate in 10 min; in (C) transport rate
was measured adding 50 μM [3H]glutamine to proteoliposomes containing 10 mM
glutamine in the presence of the indicated concentrations of Na-gluconate (○),
K-gluconate (●) or Li-acetate (□) in 10 min. Data were plotted according to
Michaelis–Menten equation. Results are means ± S.D. of three experiments.
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detergent for solubilization, C12E8, was proven by the functional charac-
terization and correlated well with previous studies conducted on the
rASCT2 solubilized in its active form from rat kidney membranes [17].
Moreover, the puriﬁed hASCT2 was eluted from Superdex 200 chroma-
tography as a 150 kDa oligomeric form suggesting that the protein
tends to form trimers. This observation is in agreement with the data
obtained on the GltPh transporter of P. horikoshii [6] and to the homology
structural model of rASCT2 [9].
To obtain functional information on the recombinant hASCT2 we
have performed reconstitution into proteoliposomes which gives the
possibility, as above mentioned, to better control several experimental
conditions. Indeed, virtually all the reconstituted transporter molecules
are inserted in the lipid bilayer of the liposomes with the same orienta-
tion of the nativemembrane (right-side-out) as suggested by the essen-
tial requirement of external Na+ for transport (Fig. 9C), whichcorrelates with the presence of Na+ in the extracellular compartment;
accordingly, single Km values are observed both outside and inside.
Similar orientation was previously found for other reconstituted trans-
porters [4,17,26,36]. However, deﬁnitive proofs of protein orientation
will be given by structure/function relationship studies. The unidirec-
tional insertion of transport proteins in the membrane is probably
guaranteed by the slow process of proteoliposome formation starting
from mixed micelles or destabilized liposomes. The insertion of the
protein into the bilayer is also inﬂuenced by the asymmetrical structure
of the protein itself together with the small radius of the starting
micelles.
The basic functional properties of the reconstituted transporter, i.e.,
the Na+-dependence, intolerance for substitution of Na+ with Li+ and
K+, the speciﬁcity for neutral amino acids, and the lack of inhibition
by the amino acid analogs MeAIB and BCH, correspond to those de-
scribed in cell systems so far [3,12]. On the other hand, some important
novel information on the hASCT2 has been obtained in the study
presented here. In particular, besides the already documented speciﬁc-
ity for glutamine, alanine, serine, threonine and cysteine, an asymmetric
behavior with respect to the transported amino acids has been
highlighted. In particular, speciﬁc amino acids such as cysteine, alanine,
valine and methionine can be translocated from outside to inside of
proteoliposomes, but not vice-versa. This ﬁnding suggests that
hASCT2 provides cells with these amino acids exporting glutamine,
threonine, serine or asparagine on the basis of metabolic needs of cells
or the amino acid concentrations. At the same time, the bi-directional
transport of glutamine is in agreement with the role proposed for
ASCT2 in astrocytes and as a general mechanism of small amino acid
reabsorption [1,14,37,38]. Also serine, asparagine and threonine are
bi-directionally translocated in line with the role designed for ASCT2,
together with LAT1 in the mTOR pathway which controls several cell
functions [2]. It has been found that Na+ stimulates the glutamine
antiport also from the internal side to some extent, even though at a
concentration higher than the intracellular Na+ concentration. This
may be explained either by sodium counter-transport, as previously
found for ASCT1 [39] or by allosteric mechanism. In this work the exter-
nal Km for glutamine of hASCT2 has been measured and found to be in
the same range as that measured in cell systems [2,12]. Moreover, by
using the proteoliposome assay, the internal Km for glutamine, so far
unknown, has been determined to be twenty times higher than the ex-
ternal one. This reﬂects the difference between the extra- and intracel-
lular concentration of glutamine and other amino acids [40]. Moreover,
the difference between the external and internal Kmvalues is in favor of
the functional asymmetry of the transporter and is in agreement with
the structural asymmetry of the hASCT2 protein (Fig. 10), which
shows a cone-shaped form enlarged towards the extracellular side.
The proteoliposome method allowed further insights in the structure–
function relationship. Indeed, the reconstituted transporter, has been
shown to be strongly inhibited by hydrophilic thiol speciﬁc reagents,
but much less by hydrophobic ones or by the amino speciﬁc reagent
PLP. These data indicates that the Cys residues involved in the observed
inhibition should be located in a hydrophilic environment accessible
from the extracellular space. On the basis of the homology model,
Cys395 is the only Cys residue exposed towards the extracellular envi-
ronment (Fig. 10), thus, it might be involved in the interaction with
the hydrophilic SH reagents and inactivation of the transporter. Even
though this is a speculative consideration, it correlates well with the lo-
cation of Cys395 in the middle of two helical hairpins (Fig. 10 dark gray
structure) whose homologues in the GltPh have been recognized as a
mobile structure involved in the conformational changes allowing sub-
strate transport [41].
By comparison with the rASCT2 some differences arose such as the
Km values which are lower for hASCT2 than those of the rat counter-
part, as well as the sensitivity to DEPC that inhibits rASCT2 but not the
human counterpart. Moreover the hASCT2 is not regulated by intracel-
lular ATP as observed for the rat protein. This can be explained by the
Fig. 10. Homology structural model of hASCT2. Ribbon diagram viewing the transporter from the lateral side (A) or by the intracellular side (B); Cys395 is highlighted in black. The
structure homologous to the sequence segment from HP (helical hairpin) 1 to HP2 of GltPh [6,40] is highlighted in dark gray. The homology model has been represented using the
molecular program SpdbViewer 4.01.
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the homologue protein from rat. In fact, the N-terminal sequence of the
rat protein, which contains a nucleotide binding motif [17] presents
some differences with respect to the human protein. Regulation of
hASCT2has been described in cell systems but no evidence of direct effec-
tors on the activity of the transport proteins is so far presented [42–44].
Noteworthy, ASCT2 represents a potential target for cancer therapy (see
Introduction). ASCT2 over-expression has been linked to the tumor sup-
pressor pRb/E2F pathway [45]. In this context, and in linewith themolec-
ular screening on the rat isoform [19], the reconstituted hASCT2 will be
very helpful for testing drugs and xenobiotics of relevance for human
health. This could allow the identiﬁcation of possible speciﬁc inhibitors
of hASCT2 activity, in order to elicit apoptosis in cancer cells. The availabil-
ity of recombinant proteins also allows site-directed mutagenesis on the
human ASCT2. Applying such methods will shed further light on the in-
volvement of hASCT2 in pathophysiology as well as in deﬁningmolecular
mechanisms of transport and structural details such as the actual
oligomeric form of the protein. However, only X-ray diffraction analysis
of hASCT2 crystals could deﬁnitively give information on the three-
dimensional structure of the transporter. The high level of production of
the functional protein in a homogeneous puriﬁed fraction allows crystal-
lographic screening for this purpose. The homology structure and, when
available, the high-resolution structurewill in addition be used in docking
strategies for fast analysis of transporter-inhibitor interactions, which
could be validated in proteoliposomes.
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